KIF5B
ENSG00000170759
Target class
Other cytosolic protein
Chromosome
10
Approved drugs
2
Clinical candidates (approved and in development)
2
- Approved drugs
- 2
- Clinical candidates (approved and in development)
- 2
- Chemical probe available
- No
- Target name
- KIF5B
- Gene name
- Kinesin family member 5B
- Gene symbol
- KIF5B
- Previous gene symbols
- KNS1
- Protein name
- Kinesin-1 heavy chain (Conventional kinesin heavy chain) (Ubiquitous kinesin heavy chain) (UKHC)
- KNS
- uKHC
- Gene biotype
- Protein coding
- Gene family
- Kinesins
- Target class
- Other cytosolic protein
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 195.33
- Tissue specificity (Gini)
- 0.25
- Tissue specificity (tau)
- 0.65
- KEGG gene identifiers
- hsa:3799
- Protein interaction confidence
- 0.843643
- Protein interaction partners
- 56
- R-HSA-2132295
- R-HSA-264876
- R-HSA-5625970
- R-HSA-6811434
- R-HSA-9725370
- R-HSA-983189
- End position
- 32056454
- Start position
- 32009014
- Chromosome
- 10
- Strand
- Reverse
- Cytoplasm, cytoskeleton . Cytolytic granule membrane . Lysosome membrane
- Peripheral membrane protein
- Cytoplasmic side . Note=Uniformly distributed between soma and neurites in hippocampal neurons. .
- Centriolar satellite
- Cytosol
- End piece
- PubMed 24088571
- PubMed 22172677
- Tissue specificity (tau)
- 0.649742
- Expression inequality (Gini)
- 0.250204
Expression in transcripts per million
- Brain - Spinal cord (cervical c-1)
- 195.33
- Artery - Tibial
- 151.92
- Colon - Sigmoid
- 132.44
- Esophagus - Muscularis
- 125.18
- Cells - Cultured fibroblasts
- 120.36
Expression in transcripts per million
- Brain - Spinal cord (cervical c-1)195.33
- Artery - Tibial151.92
- Colon - Sigmoid132.44
- Esophagus - Muscularis125.18
- Cells - Cultured fibroblasts120.36
- Artery - Aorta113.91
- Brain - Substantia nigra105.77
- Artery - Coronary105.1
- Nerve - Tibial100.3
- Fallopian Tube99.78
- Uterus99.26
- Esophagus - Gastroesophageal Junction97.16
- Cervix - Ectocervix94.56
- Lung82.71
- Brain - Amygdala82.36
- Bladder81.22
- Cervix - Endocervix80.41
- Brain - Hippocampus71.39
- Prostate71.12
- Colon - Transverse70.88
- Brain - Hypothalamus70.16
- Adipose - Subcutaneous68.41
- Brain - Cortex68.4
- Vagina67.18
- Testis66.95
And 29 more, listed on the interactive page.
- GO:0007018
- GO:0032418
- GO:0042267
- GO:0042391
- GO:0043268
- GO:0047496
- GO:0051642
- GO:1903078
- GO:0005765
- GO:0005829
- GO:0005871
- GO:0016020
- GO:0031982
- GO:0101004
- GO:0003777
- GO:0005515
- GO:0008017
- GO:0042802
- GO:0045296
Related records
Trials (60)
- A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants
- A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants
- A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC
- A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants
- A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer
- A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants
- A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
- A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male Participants
- A Study of Effect of Food and a Proton Pump Inhibitor on Selpercatinib (LY3527723) in Healthy Participants
- A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function
- A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants
- A Study of Effects of Itraconazole and Rifampin on Selpercatinib (LY3527723) in Healthy Participants
- A Study of Effects of Selpercatinib (LY3527723) on Midazolam in Healthy Participants
- A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants
- A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants
- A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
- A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
- A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).
- A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
- A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Drugs (2)
- Pralsetinib Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor
- Selpercatinib Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor